Some people say that amlodipine has a protective effect on the heart, and left-handedness is only a blood pressure reduction. Is it really?   I. Levamlodipine Amlodipine, a third-generation long-acting calcium antagonist, is a commonly used drug for the treatment of hypertension and angina pectoris. The half-life is as… Continue Reading Amlodipine protects the heart, and levoamlodipine can only reduce blood pressure?

  The regulation of human blood glucose concentration is mainly achieved by the mutual restriction of insulin and glucagon at multiple levels. Among them, insulin produced by islet β cells is responsible for promoting blood glucose absorption and lowering blood glucose concentration. Islet beta cell destruction or dysfunction can lead… Continue Reading Nature’s paper: Treating diabetes with cell therapy is worth looking forward to

  Pancreatic cancer is one of the most malignant tumors. It is called “the king of cancer” because of its low survival rate and extremely short survival period. It is usually asymptomatic in the early stage and often spreads to the whole body when it is diagnosed. Pancreatic cancer is… Continue Reading Nature: The king of cancer also has weakness

  Metformin is the most widely used type 2 diabetes drug, and is known as a “magic medicine” because of its anti-cancer and anti-aging effects. Now, scientists from the University of Dundee in the UK have recently discovered that metformin can also reverse the thickening of harmful myocardial walls that… Continue Reading Metformin may reduce the risk of heart disease, the first clinical trial results in top journals

  Following the announcement on February 12 that the ASK1 inhibitor selonsertib (GS4997) missed the first-order endpoint in its first phase III clinical trial (STELLAR-4), Gilead announced on April 25 that selonsertib was in another STELLAR-3 study. The scheduled clinical endpoint of 48 weeks was not reached.   STELLAR-4 study… Continue Reading Gilead NASH new drug selonsertib second phase III clinical failure

  On April 25, Lilly announced that it is advancing the global withdrawal of the new soft tissue sarcoma drug Lartruvo (olaratumab). Lilly’s decision was mainly due to the fact that in the large phase III ANNOUNCE study after marketing, olaratumab failed to show survival benefit in both the treated… Continue Reading Lilly’s soft tissue sarcoma drug Olaratumab will withdraw from the world

  Pharmaceutical companies usually do their utmost to extend the patent protection period to prevent the listing of generic drugs in order to gain market exclusive rights. Fiercepharma recently released a list of TOP10 drugs that lost exclusive rights in the United States in 2019, listing 10 varieties from seven… Continue Reading Top10 of drugs that lost exclusive rights in the US market in 2019

  Bispecific antibody (BsAb) refers to an antibody molecule that can specifically bind two antigens or two epitopes at the same time. In theory, it can exert synergistic effect of two monoclonal antibodies, which is one of the most popular new drug research and development investment direction in the industry.… Continue Reading Bispecific antibody boom

  At the end of 2018, Celgene understated the monotherapy of CD47 monoclonal antibody CC-90002 for the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). On the day of the suspension of the CC-90002 trial, shares in other CD47 companies such as Trillium, Forty Seven, and Surface… Continue Reading Second generation CD47 antibody: a new hot spot for tumor immunotherapy

  Metabolism involves a series of biochemical reactions that convert nutrients into metabolites that play an important role in maintaining cellular homeostasis and in response to intracellular and extracellular stimuli. Metabolic changes are one of the important features of tumors. In order to maintain sustained proliferation, tumor cells must adjust… Continue Reading The next wave of cancer immunotherapy – regulating metabolism